Drug Trial Radar · NCT07811908
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Feb 12, 2026
Primary completion
Feb 4, 2027
Study completion Feb 18, 2027
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Sep 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 2 years, up to 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was Cohort C2 of the Platform study (NCT05750628) to evaluate the efficacy and safety of Cipargamin + KLU156 in participants with uncomplicated Plasmodium falciparum malaria.
Conditions
- Uncomplicated Plasmodium Falciparum Malaria
Interventions
KAE609Drug
oral capsules administered in combination with KLU156
SoC (Coartem)Drug
Standard of Care
KLU156Drug
oral sachet formulation (KAF156+LUM-SDF) administered in combination with cipargamin (KAE609)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Polymerase chain reaction (PCR) corrected adequate clinical and parasitological response (ACPR)Time frame: Day 29
Locations
13 sites in 7 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Banfora, Burkina Faso · Recruiting
Novartis Investigative Site
Nanoro, Burkina Faso · Recruiting
Novartis Investigative Site
Abidjan, Côte d’Ivoire · Recruiting
Novartis Investigative Site
Azaguié, Côte d’Ivoire · Recruiting
Novartis Investigative Site
Lambaréné, Gabon · Not yet recruiting
Novartis Investigative Site
Libreville, Gabon · Not yet recruiting
Novartis Investigative Site
Kintampo, Ghana · Not yet recruiting
Novartis Investigative Site
Navrongo, Ghana · Not yet recruiting
Novartis Investigative Site
Ahero, Kenya · Not yet recruiting
Novartis Investigative Site
Kisumu, Kenya · Not yet recruiting
Novartis Investigative Site
Kigali, Rwanda · Recruiting
Novartis Investigative Site
Kampala, Uganda · Not yet recruiting
Novartis Investigative Site
Tororo, Uganda · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.